VANCOUVER, Dec. 12, 2018 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity“) (CSE: CGN; FWB: 1UB; OTCQB: CGNSF) today announced that Chief Operations Officer, Dr. Tom Sawyer, has been invited to speak at the Genesis Life Science & Healthcare Conference in London, UK on December 13th, 2018.
Founded almost two decades ago, Genesis 2018 will have an overarching theme of ‘Driving success in Life Sciences & Healthcare: Convergence of Technology, Investment and Talent‘ and assemble senior executives and decision makers from across the Life Science and Healthcare field to present, discuss and demonstrate their collective insight and thought leadership for the sector, themselves and their stakeholders.
Dr. Sawyer will speak alongside a notable panel including participants from the University of Cambridge and University College London on the subject of ‘Diagnostics and Cognitive Monitoring for Dementia Patients’. The presentation will include details of Cognetivity’s unique AI-based platform for the measurement of cognitive performance and its potential as a large-scale screening tool to allow early stage dementia diagnosis, as well as research data validating its scientific approach. The session will be at 14:00 on the 13th of December at the QEII Centre in Westminster, London, UK
Cognetivity will be represented at the conference alongside some of the world’s largest global healthcare organizations including GlaxoSmithKline, AstraZeneca and Johnson & Johnson.
In addition, Cognetivity granted 100,000 stock options to an employee and 150,000 stock options to a consultant of the Company exercisable at a price of $0.41 per common share for a period of five and three years from the date of grant respectively.
About Cognetivity Neurosciences Ltd.
Cognetivity is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA) for use in medical and commercial environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity aims to develop the ICA through planned clinical studies to the market in North America and Europe.
For more information please visit – www.cognetivity.com
ON BEHALF OF THE BOARD
Chief Executive Officer and Director
FORWARD LOOKING STATEMENTS:
The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.
The Exchange does not accept responsibility for the adequacy or accuracy of this release
SOURCE Cognetivity Neurosciences Ltd